Literature DB >> 7943099

Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy.

T G Di Sessa1, M L Moretti, A Khoury, D A Pulliam, K L Arheart, B M Sibai.   

Abstract

OBJECTIVE: Our purpose was to evaluate cardiac function in fetuses exposed to low-dose aspirin. STUDY
DESIGN: To assess its efficacy in preventing preeclampsia, 60 mg/day aspirin or a matching placebo was administered to women in a double-blind fashion during the second and third trimesters. As a part of this study, 146 echo Doppler studies were performed on 63 fetuses from 15 to 40 weeks' gestation. These studies allowed assessment of systolic and diastolic cardiac function. Cardiac function was also assessed in 87 neonates.
RESULTS: Throughout gestation ductus arteriosus flow velocity, right ventricular output and diastolic area, and left ventricular output and diastolic area all increased and were similar in both aspirin- and placebo-exposed fetuses. Fetal diastolic flow velocities were also alike in both groups. The two groups had similar gestational ages at delivery (39.2 +/- 2.3 vs 38.7 +/- 2.7 weeks) and birth weights (3174 +/- 575 vs 3105 +/- 579 gm, respectively). Furthermore, there was no difference in fractional shortening, cardiac output, prevalence of tricuspid regurgitation, or patency of the ductus arteriosus at birth between the two groups.
CONCLUSION: The circulation of fetuses and newborns is not affected adversely by exposure to low-dose aspirin during gestation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7943099     DOI: 10.1016/s0002-9378(94)70056-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

Review 1.  Aspirin Use in Women: Current Perspectives and Future Directions.

Authors:  Amy Sarma; Nandita S Scott
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

Review 2.  Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?

Authors:  M Ostensen; R Ramsey-Goldman
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

3.  Antiplatelet agents for preventing pre-eclampsia and its complications.

Authors:  Lelia Duley; Shireen Meher; Kylie E Hunter; Anna Lene Seidler; Lisa M Askie
Journal:  Cochrane Database Syst Rev       Date:  2019-10-30

4.  Anti-inflammatory and immunosuppressive drugs and reproduction.

Authors:  Monika Østensen; Munther Khamashta; Michael Lockshin; Ann Parke; Antonio Brucato; Howard Carp; Andrea Doria; Raj Rai; Pierluigi Meroni; Irene Cetin; Ronald Derksen; Ware Branch; Mario Motta; Caroline Gordon; Guillermo Ruiz-Irastorza; Arsenio Spinillo; Deborah Friedman; Rolando Cimaz; Andrew Czeizel; Jean Charles Piette; Ricard Cervera; Roger A Levy; Maurizio Clementi; Sara De Carolis; Michelle Petri; Yehuda Shoenfeld; David Faden; Guido Valesini; Angela Tincani
Journal:  Arthritis Res Ther       Date:  2006-05-11       Impact factor: 5.156

5.  Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE).

Authors:  Neil O'Gorman; David Wright; Daniel L Rolnik; Kypros H Nicolaides; Liona C Poon
Journal:  BMJ Open       Date:  2016-06-28       Impact factor: 2.692

Review 6.  Aspirin for Prevention of Preeclampsia.

Authors:  A Atallah; E Lecarpentier; F Goffinet; M Doret-Dion; P Gaucherand; V Tsatsaris
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

Review 7.  Aspirin for prevention of preeclampsia in lupus pregnancy.

Authors:  Amelie M Schramm; Megan E B Clowse
Journal:  Autoimmune Dis       Date:  2014-03-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.